Last updated: 2026-09-16 21:09:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
SELLAS Life Sciences Group, Inc. (SLS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $11.66, with a market capitalization of $2.37B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.39 to $15.88. This page covers its latest market performance, valuation, price trends and company information.
$2.37B | |
$11.24 | |
$25,750.00 | |
$0.50 | |
$11.29 | |
4.65M | |
8.43M | |
-- | |
$15.88 | |
$1.39 | |
-- | |
-- |
SELLAS Life Sciences Group, Inc. (SLS) is trading at $11.67 in after-hours trading as of 2026-09-16 21:07:00, up 3.33% ($0.38) from the regular-session close of $11.29.
After-hours trading shows how investors are pricing SLS after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, SELLAS Life Sciences Group, Inc. (SLS) moved from $13.86 to $11.66, representing a decline of 15.86% ($2.20).
The stock traded between $10.78 and $14.37 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 7.34 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 70.9%
SLS is currently trading at $11.66, placing it 70.9% of the way from its 52-week low of $1.39 to its 52-week high of $15.88. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 13 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of SELLAS Life Sciences Group, Inc. (SLS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.